Brian Porter

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Karel Pavelka, Alan Kivitz, Eva Dokoupilová et al. · Arthritis Research & Therapy · 2017 · 233 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan et al. · Annals of the Rheumatic Diseases · 2019 · 195 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome

Lis Ribeiro do Valle Antonelli, Yolanda D. Mahnke, Jessica N. Hodge et al. · Blood · 2010 · 182 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

Joachim Sieper, Atul Deodhar, Helena Marzo‐Ortega et al. · Annals of the Rheumatic Diseases · 2016 · 180 citations

Medicine, Clinical Sciences, Immunology +15